Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Apr 28.

Published in final edited form as: N Engl J Med. 2022 Mar 24;386(12):1109–1120. doi: 10.1056/NEJMoa2111904

Panel A shows the cumulative all-cause mortality by week 10 according to treatment strategy in the intention-to-treat population. Panel B shows a non-inferiority graph for differences in all-cause mortality at 10 weeks. The mean difference in 10-week mortality risk (absolute percentage difference) between the AmBisome and control arms and the two-sided 90% confidence intervals in both unadjusted and adjusted intention-to-treat and per-protocol analyses are shown. The dashed line indicated the prespecified 10% non-inferiority margin. Adjusted analysis adjusting for pre-specified baseline covariates of: site, age, sex, Glasgow Coma Scale, CD4 count, cerebrospinal fluid colony forming units/mL, HIV therapy status, hemoglobin, and CSF opening pressure.

Panel A shows the cumulative all-cause mortality by week 10 according to treatment strategy in the intention-to-treat population. Panel B shows a non-inferiority graph for differences in all-cause mortality at 10 weeks. The mean difference in 10-week mortality risk (absolute percentage difference) between the AmBisome and control arms and the two-sided 90% confidence intervals in both unadjusted and adjusted intention-to-treat and per-protocol analyses are shown. The dashed line indicated the prespecified 10% non-inferiority margin. Adjusted analysis adjusting for pre-specified baseline covariates of: site, age, sex, Glasgow Coma Scale, CD4 count, cerebrospinal fluid colony forming units/mL, HIV therapy status, hemoglobin, and CSF opening pressure.